JP2020125349A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020125349A5 JP2020125349A5 JP2020081156A JP2020081156A JP2020125349A5 JP 2020125349 A5 JP2020125349 A5 JP 2020125349A5 JP 2020081156 A JP2020081156 A JP 2020081156A JP 2020081156 A JP2020081156 A JP 2020081156A JP 2020125349 A5 JP2020125349 A5 JP 2020125349A5
- Authority
- JP
- Japan
- Prior art keywords
- lymphoma
- cell
- cancer
- leukemia
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 26
- 201000011510 cancer Diseases 0.000 claims 13
- 239000003795 chemical substances by application Substances 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 206010025323 Lymphomas Diseases 0.000 claims 8
- 208000024891 symptom Diseases 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 239000002955 immunomodulating agent Substances 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 5
- 229960005486 vaccine Drugs 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- 208000017604 Hodgkin disease Diseases 0.000 claims 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 claims 4
- 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 210000004907 gland Anatomy 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 239000005556 hormone Substances 0.000 claims 4
- 229940088597 hormone Drugs 0.000 claims 4
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims 4
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims 4
- 210000000214 mouth Anatomy 0.000 claims 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 210000001635 urinary tract Anatomy 0.000 claims 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 3
- 230000000259 anti-tumor effect Effects 0.000 claims 3
- 238000002659 cell therapy Methods 0.000 claims 3
- 208000015114 central nervous system disease Diseases 0.000 claims 3
- 229940121354 immunomodulator Drugs 0.000 claims 3
- 230000009933 reproductive health Effects 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 208000012609 Cowden disease Diseases 0.000 claims 2
- 201000002847 Cowden syndrome Diseases 0.000 claims 2
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims 2
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims 2
- 208000002927 Hamartoma Diseases 0.000 claims 2
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 claims 2
- 206010024305 Leukaemia monocytic Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 2
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 201000004458 Myoma Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 241000588769 Proteus <enterobacteria> Species 0.000 claims 2
- 208000007531 Proteus syndrome Diseases 0.000 claims 2
- 208000014841 Proteus-like syndrome Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 2
- 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 claims 2
- 208000000389 T-cell leukemia Diseases 0.000 claims 2
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 claims 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 2
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims 2
- 208000008383 Wilms tumor Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 201000005188 adrenal gland cancer Diseases 0.000 claims 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 2
- 201000006966 adult T-cell leukemia Diseases 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 210000000436 anus Anatomy 0.000 claims 2
- 210000000941 bile Anatomy 0.000 claims 2
- 210000000013 bile duct Anatomy 0.000 claims 2
- 201000000053 blastoma Diseases 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 210000000621 bronchi Anatomy 0.000 claims 2
- 210000005252 bulbus oculi Anatomy 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000022131 cell cycle Effects 0.000 claims 2
- 210000003679 cervix uteri Anatomy 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 201000008184 embryoma Diseases 0.000 claims 2
- 210000000416 exudates and transudate Anatomy 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 230000002518 glial effect Effects 0.000 claims 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims 2
- 210000003128 head Anatomy 0.000 claims 2
- 210000002216 heart Anatomy 0.000 claims 2
- 201000002222 hemangioblastoma Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000000366 juvenile effect Effects 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 210000000088 lip Anatomy 0.000 claims 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000002503 metabolic effect Effects 0.000 claims 2
- 201000006894 monocytic leukemia Diseases 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 210000003928 nasal cavity Anatomy 0.000 claims 2
- 210000003739 neck Anatomy 0.000 claims 2
- 201000008026 nephroblastoma Diseases 0.000 claims 2
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 claims 2
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 230000000849 parathyroid Effects 0.000 claims 2
- 210000003800 pharynx Anatomy 0.000 claims 2
- 210000003635 pituitary gland Anatomy 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 230000019491 signal transduction Effects 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 210000000813 small intestine Anatomy 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 210000000278 spinal cord Anatomy 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 210000004500 stellate cell Anatomy 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 210000001550 testis Anatomy 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 210000001215 vagina Anatomy 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- XEIVCDDCSGGZSG-UHFFFAOYSA-N 7-[3-[(3-formylphenoxy)methyl]-1,5-dimethylpyrazol-4-yl]-3-(3-naphthalen-1-yloxypropyl)-1H-indole-2-carboxylic acid Chemical compound Cc1c(c(COc2cccc(C=O)c2)nn1C)-c1cccc2c(CCCOc3cccc4ccccc34)c([nH]c12)C(O)=O XEIVCDDCSGGZSG-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000027626 Neurocognitive disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 206010000210 abortion Diseases 0.000 claims 1
- 231100000176 abortion Toxicity 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 125000002560 nitrile group Chemical group 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000000861 pro-apoptotic effect Effects 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000002476 tumorcidal effect Effects 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1419570.5A GB201419570D0 (en) | 2014-11-03 | 2014-11-03 | Pharmaceutical compound |
| GB1419570.5 | 2014-11-03 | ||
| GBGB1507883.5A GB201507883D0 (en) | 2015-05-08 | 2015-05-08 | Pharmaceutical compound |
| GB1507883.5 | 2015-05-08 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017542315A Division JP6701214B2 (ja) | 2014-11-03 | 2015-11-02 | 医薬化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020125349A JP2020125349A (ja) | 2020-08-20 |
| JP2020125349A5 true JP2020125349A5 (enExample) | 2020-10-15 |
| JP6994538B2 JP6994538B2 (ja) | 2022-01-14 |
Family
ID=54476948
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017542315A Active JP6701214B2 (ja) | 2014-11-03 | 2015-11-02 | 医薬化合物 |
| JP2020081156A Active JP6994538B2 (ja) | 2014-11-03 | 2020-05-01 | 医薬化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017542315A Active JP6701214B2 (ja) | 2014-11-03 | 2015-11-02 | 医薬化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10590086B2 (enExample) |
| EP (1) | EP3215156B1 (enExample) |
| JP (2) | JP6701214B2 (enExample) |
| KR (1) | KR102602947B1 (enExample) |
| CN (2) | CN111943890B (enExample) |
| AU (1) | AU2015341913B2 (enExample) |
| CA (1) | CA2965741C (enExample) |
| MX (1) | MX390081B (enExample) |
| RU (1) | RU2719446C2 (enExample) |
| WO (1) | WO2016071293A2 (enExample) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ582150A (en) | 2007-06-18 | 2012-08-31 | Msd Oss Bv | Antibodies to human programmed death receptor pd-1 |
| US10590086B2 (en) | 2014-11-03 | 2020-03-17 | Iomet Pharma Ltd. | Pharmaceutical compound |
| JO3637B1 (ar) | 2015-04-28 | 2020-08-27 | Janssen Sciences Ireland Uc | مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv |
| KR101997241B1 (ko) | 2015-05-21 | 2019-07-09 | 하푼 테라퓨틱스, 인크. | 삼중특이성 결합 단백질 및 사용 방법 |
| MX2021006804A (es) | 2015-12-17 | 2023-01-13 | Merck Patent Gmbh | Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios. |
| CN107033087B (zh) * | 2016-02-04 | 2020-09-04 | 西华大学 | 1h-吲唑-4-胺类化合物及其作为ido抑制剂的用途 |
| CN107619392B (zh) * | 2016-07-15 | 2021-01-01 | 西华大学 | 1h-吲唑-4-醚类化合物及其作为ido抑制剂的用途 |
| WO2017133258A1 (zh) * | 2016-02-04 | 2017-08-10 | 西华大学 | 1h-吲唑类衍生物及其作为ido抑制剂的用途 |
| CN107840826B (zh) * | 2016-09-19 | 2021-07-09 | 西华大学 | 1h-吲唑类衍生物及其作为ido抑制剂的用途 |
| BR112018071602B1 (pt) | 2016-04-29 | 2024-02-27 | Iomet Pharma Ltd. | Compostos de imidazopiridina substituídos, sua composição e seus usos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3- dioxigenase |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| CN107556244B (zh) * | 2016-07-01 | 2021-09-03 | 上海迪诺医药科技有限公司 | 并环化合物、其药物组合物及应用 |
| EP3269714A1 (en) | 2016-07-13 | 2018-01-17 | Netherlands Translational Research Center B.V. | Inhibitors of tryptophan 2,3-dioxygenase |
| CN107674029A (zh) * | 2016-08-02 | 2018-02-09 | 上海迪诺医药科技有限公司 | 多环化合物、其药物组合物及应用 |
| RU2758686C2 (ru) | 2016-08-08 | 2021-11-01 | Мерк Патент Гмбх | Антагонисты tlr7/8 и их применение |
| AU2017315572B2 (en) * | 2016-08-23 | 2021-07-15 | Beijing Innocare Pharma Tech Co., Ltd. | Fused heterocyclic derivative, preparation method therefor and medical use thereof |
| TW201815766A (zh) * | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症 |
| CN109952300B (zh) * | 2016-09-24 | 2022-01-18 | 百济神州有限公司 | 5或8-取代的咪唑并[1,5-a]吡啶 |
| US10961238B2 (en) | 2016-10-26 | 2021-03-30 | E-Therapeutics Plc | Modulators of hedgehog (Hh) signaling pathway |
| JP2020506895A (ja) | 2017-01-17 | 2020-03-05 | ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | インドールアミン２，３−ジオキシゲナーゼおよび／またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物 |
| KR102294129B1 (ko) * | 2017-03-16 | 2021-08-27 | 국제약품 주식회사 | N-벤질-n-페녹시카르보닐-페닐설폰아마이드 유도체 및 그를 포함하는 약제학적 조성물 |
| CN108689937B (zh) * | 2017-04-10 | 2021-09-17 | 西华大学 | 吲唑类化合物及其在制备ido抑制剂类药物上的用途 |
| CN108689938B (zh) * | 2017-04-10 | 2021-07-30 | 西华大学 | 多取代的吲唑类化合物及其作为ido抑制剂的用途 |
| CN108689936B (zh) * | 2017-04-10 | 2021-09-10 | 西华大学 | 含氮取代基的吲唑类化合物及其作为ido抑制剂的用途 |
| AU2018265856B2 (en) | 2017-05-12 | 2023-04-27 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| CA3060989A1 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
| EP3645538A1 (en) * | 2017-06-28 | 2020-05-06 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of indoleamine 2,3-dioxygenase |
| BR112020002265A2 (pt) | 2017-08-01 | 2020-07-28 | Theravance Biopharma R&D Ip, Llc | compostos pirazólicos e triazólicos bicíclicos como inibidores de jak quiinase |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| WO2019075359A1 (en) | 2017-10-13 | 2019-04-18 | Harpoon Therapeutics, Inc. | TRISPECIFIC PROTEINS AND METHODS OF USE |
| EP3697791A4 (en) * | 2017-10-19 | 2021-06-16 | JS Innopharm (Shanghai) Ltd. | HETEROCYCLIC COMPOUNDS, COMPOSITIONS INCLUDING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF |
| JP7306634B2 (ja) | 2017-10-19 | 2023-07-11 | 一般社団法人ファルマバレープロジェクト支援機構 | Ｉｄｏ／ｔｄｏ阻害剤 |
| US11759461B2 (en) | 2017-10-30 | 2023-09-19 | The Scripps Research Institute | Small molecule inhibitors of cancer stem cells and mesenchymal cancer types |
| CN111386114A (zh) | 2017-11-25 | 2020-07-07 | 百济神州有限公司 | 作为吲哚胺2,3-双加氧酶的选择性抑制剂的新颖苯并咪唑 |
| TW201932470A (zh) | 2017-11-29 | 2019-08-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 具有抗ｒｓｖ活性之吡唑并嘧啶 |
| CN108586378B (zh) | 2018-01-22 | 2020-06-19 | 南京华威医药科技集团有限公司 | 吲哚胺2,3-双加氧化酶抑制剂及其制备方法和用途 |
| KR20200116481A (ko) | 2018-01-29 | 2020-10-12 | 메르크 파텐트 게엠베하 | Gcn2 억제제 및 이의 용도 |
| US10793563B2 (en) | 2018-01-29 | 2020-10-06 | Merck Patent Gmbh | GCN2 inhibitors and uses thereof |
| EA202091835A1 (ru) | 2018-01-31 | 2020-10-20 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Замещенные циклоалкилом пиразолопиримидины, обладающие активностью против rsv |
| SI3752501T1 (sl) | 2018-02-13 | 2023-08-31 | Gilead Sciences, Inc. | Inhibitorji pd-1/pd-l1 |
| CN110156674A (zh) * | 2018-02-13 | 2019-08-23 | 中国科学院上海有机化学研究所 | 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物 |
| EP3768666A1 (en) | 2018-03-20 | 2021-01-27 | Plexxikon Inc. | Compounds and methods for ido and tdo modulation, and indications therefor |
| CA3093130C (en) | 2018-04-19 | 2023-10-17 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| KR20210005569A (ko) | 2018-04-23 | 2021-01-14 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Rsv에 대한 활성을 갖는 헤테로방향족 화합물 |
| SI3820572T1 (sl) | 2018-07-13 | 2023-12-29 | Gilead Sciences, Inc. | Inhibitorji pd-1/pd-l1 |
| US11046649B2 (en) | 2018-07-17 | 2021-06-29 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| WO2020068729A1 (en) | 2018-09-25 | 2020-04-02 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators |
| BR112021005769A2 (pt) | 2018-09-25 | 2021-07-06 | Harpoon Therapeutics Inc | proteínas de ligação a dll3 e métodos de uso |
| JP7158577B2 (ja) | 2018-10-24 | 2022-10-21 | ギリアード サイエンシーズ， インコーポレイテッド | Ｐｄ－１／ｐｄ－ｌ１阻害剤 |
| US12091405B2 (en) | 2018-11-01 | 2024-09-17 | Merck Sharp & Dohme Llc | Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors |
| CN111285808B (zh) * | 2018-12-07 | 2023-06-23 | 西华大学 | 4位芳杂环取代的吲唑类化合物及其作为ido/tdo双重抑制剂的用途 |
| JP2022518741A (ja) | 2019-01-23 | 2022-03-16 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | ＪＡＫキナーゼ阻害剤としてのイミダゾ［１，５－ａ］ピリジン、１，２，４－トリアゾロ［４，３－ａ］ピリジンおよびイミダゾ［１，５－ａ］ピラジン |
| CN111689901A (zh) * | 2019-03-13 | 2020-09-22 | 西华大学 | 一类具有tdo、ido1双重抑制活性的化合物及制备治疗神经退行性疾病药物的用途 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| EP4046688B1 (en) * | 2019-10-18 | 2025-04-09 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2021113436A1 (en) * | 2019-12-04 | 2021-06-10 | Arcus Biosciences, Inc. | Inhibitors of hif-2alpha |
| US20220396577A1 (en) * | 2019-12-17 | 2022-12-15 | Merck Sharp & Dohme Llc | Novel substituted 1,3-8-triazaspiro[4,5] decane-2,4-dione compounds as indoleamine 2,3-dioxygenase (ido) and/or tryptophan 2,3-dioxygenase (tdo) inhibitors |
| US11911376B2 (en) | 2020-03-30 | 2024-02-27 | The Regents Of The University Of Colorado | Methods for preventing and treating retinal damage |
| KR20230026479A (ko) * | 2020-06-22 | 2023-02-24 | 에프. 호프만-라 로슈 아게 | 설폰 유도체 |
| US11839659B2 (en) | 2020-07-02 | 2023-12-12 | Northwestern University | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein |
| CA3182579A1 (en) | 2020-07-07 | 2022-01-13 | Ugur Sahin | Therapeutic rna for hpv-positive cancer |
| CN114057641B (zh) * | 2020-08-07 | 2025-02-18 | 上海挚盟医药科技有限公司 | 作为钾通道调节剂的四氢异喹啉类化合物及其制备和应用 |
| IL299091A (en) | 2020-08-14 | 2023-02-01 | Novartis Ag | Heteroaryl substituted spiropiperidinyl derivatives and their medicinal uses |
| JP2023543140A (ja) * | 2020-08-31 | 2023-10-13 | ビューポイント セラピューティクス， インコーポレイテッド | 眼疾患を治療するための化合物および製剤 |
| JP2023549738A (ja) | 2020-10-30 | 2023-11-29 | １シーバイオ， インコーポレイテッド | エクトヌクレオチドピロホスファターゼ－ホスホジエステラーゼ－１（ｅｎｐｐ１）阻害物質及びそれらの使用 |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
| US20240091202A1 (en) | 2021-03-05 | 2024-03-21 | Universität Basel | Compositions for the treatment of ebv associated diseases or conditions |
| EP4326721A1 (en) * | 2021-04-22 | 2024-02-28 | Protego Biopharma, Inc. | Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis |
| MX2024000674A (es) | 2021-07-13 | 2024-02-07 | BioNTech SE | Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion. |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| PE20250603A1 (es) | 2022-01-18 | 2025-02-26 | Maze Therapeutics Inc | Inhibidores de apol1 y metodos de uso |
| CN119156403A (zh) | 2022-03-08 | 2024-12-17 | 阿伦蒂斯治疗股份公司 | 抗紧密连接蛋白-1抗体增加t细胞可用性的用途 |
| EP4594320A1 (en) * | 2022-09-30 | 2025-08-06 | Genentech Inc. | Hydantoin modulators of cholesterol biosynthesis and their use for promoting remyelination |
| IL321098A (en) | 2022-12-14 | 2025-07-01 | Astellas Pharma Europe Bv | Combination therapy including bispecific binding agents that bind to CLDN18.2- and CD3- and immune checkpoint inhibitors |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US685109A (en) * | 1901-08-15 | 1901-10-22 | Joseph P Cornelius | Car-fender. |
| US1540442A (en) * | 1923-03-12 | 1925-06-02 | Leo T Ward | Ventilating window lock |
| WO1998035942A1 (en) * | 1997-02-18 | 1998-08-20 | American Home Products Corporation | 4-aminoethoxyindazole derivatives |
| EP0999208A4 (en) * | 1997-05-30 | 2001-08-08 | Meiji Seika Kaisha | NITROGEN-BASED HETEROCYCLIC COMPOUNDS AND MEDICINES FOR TREATING HYPERLIPEMIA THAT CONTAIN THEM |
| WO2000071517A1 (en) | 1999-05-24 | 2000-11-30 | Mitsubishi Pharma Corporation | Phenoxypropylamine compounds |
| WO2001070728A1 (en) * | 2000-03-23 | 2001-09-27 | Sanofi-Synthelabo | 2-[nitrogen-heterocyclic]pyrimidone derivatives |
| US7034029B2 (en) | 2000-11-02 | 2006-04-25 | Wyeth | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
| NZ525592A (en) * | 2000-11-02 | 2004-07-30 | Wyeth Corp | 1-Aryl- or 1-alkylsufonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
| US6864255B2 (en) * | 2001-04-11 | 2005-03-08 | Amgen Inc. | Substituted triazinyl amide derivatives and methods of use |
| JPWO2002100833A1 (ja) * | 2001-06-12 | 2004-09-24 | 住友製薬株式会社 | Ｒｈｏキナーゼ阻害剤 |
| FR2836914B1 (fr) * | 2002-03-11 | 2008-03-14 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| NZ541699A (en) * | 2003-02-14 | 2009-01-31 | Wyeth Corp | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands |
| US20050182061A1 (en) * | 2003-10-02 | 2005-08-18 | Jeremy Green | Phthalimide compounds useful as protein kinase inhibitors |
| US20050267096A1 (en) * | 2004-05-26 | 2005-12-01 | Pfizer Inc | New indazole and indolone derivatives and their use pharmaceuticals |
| WO2005116027A2 (en) * | 2004-05-26 | 2005-12-08 | Pfizer Limted | Indazole and indolone derivatives and their use as pharmaceuticals |
| WO2006105127A2 (en) * | 2005-03-31 | 2006-10-05 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
| AR056080A1 (es) * | 2005-09-23 | 2007-09-19 | Schering Corp | 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine |
| JP2007145786A (ja) * | 2005-11-30 | 2007-06-14 | Toray Ind Inc | ピラジン誘導体及びそれを有効成分とする腎炎治療薬 |
| PE20071143A1 (es) * | 2006-01-13 | 2008-01-20 | Wyeth Corp | Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6 |
| WO2007124355A2 (en) * | 2006-04-20 | 2007-11-01 | Nova Southeastern University | Vascular endothelial receptor specific inhibitors |
| JP2008208074A (ja) * | 2007-02-27 | 2008-09-11 | Toray Ind Inc | ピラジン誘導体を有効成分とする抗がん剤 |
| AU2008256859A1 (en) | 2007-05-24 | 2008-12-04 | Memory Pharmaceuticals Corporation | 4' substituted compounds having 5-HT6 receptor affinity |
| ES2526966T3 (es) * | 2008-06-05 | 2015-01-19 | Glaxo Group Limited | Compuestos novedosos |
| WO2011067366A1 (en) * | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Indazole derivatives as pi 3 - kinase inhibitors |
| EP2507223A1 (en) * | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of p13 kinases |
| WO2012044090A2 (ko) | 2010-09-29 | 2012-04-05 | 크리스탈지노믹스(주) | 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물 |
| US9434743B2 (en) | 2012-03-02 | 2016-09-06 | Takeda Pharmaceutical Company Limited | Indazole derivatives |
| ES2579981T3 (es) | 2012-03-07 | 2016-08-18 | Merck Patent Gmbh | Derivados de triazolopirazina |
| BR112015022588A2 (pt) * | 2013-03-14 | 2017-07-18 | Newlink Genetics Corp | composto, composição farmacêutica, e, método para tratamento de imunossupressão em um indivíduo |
| US10590086B2 (en) | 2014-11-03 | 2020-03-17 | Iomet Pharma Ltd. | Pharmaceutical compound |
-
2015
- 2015-11-02 US US15/524,142 patent/US10590086B2/en active Active
- 2015-11-02 AU AU2015341913A patent/AU2015341913B2/en active Active
- 2015-11-02 CN CN202010871093.0A patent/CN111943890B/zh active Active
- 2015-11-02 MX MX2017005719A patent/MX390081B/es unknown
- 2015-11-02 CN CN201580072167.1A patent/CN107108556B/zh active Active
- 2015-11-02 EP EP15790910.2A patent/EP3215156B1/en active Active
- 2015-11-02 CA CA2965741A patent/CA2965741C/en active Active
- 2015-11-02 RU RU2017118160A patent/RU2719446C2/ru active
- 2015-11-02 KR KR1020177014762A patent/KR102602947B1/ko active Active
- 2015-11-02 WO PCT/EP2015/075486 patent/WO2016071293A2/en not_active Ceased
- 2015-11-02 JP JP2017542315A patent/JP6701214B2/ja active Active
-
2020
- 2020-02-03 US US16/780,349 patent/US11130738B2/en active Active
- 2020-05-01 JP JP2020081156A patent/JP6994538B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020125349A5 (enExample) | ||
| CN107108556B (zh) | 药用化合物 | |
| JP2020504716A5 (enExample) | ||
| RU2750727C9 (ru) | Фармацевтически активные соединения в качестве ингибиторов рецепторной тирозинкиназы семейства там | |
| HRP20201621T1 (hr) | Derivati indola za uporabu u medicini | |
| BR112020013672A2 (pt) | compostos, composições, e métodos para tratamento de doenças que envolvem tecidos afetados por ácidos ou hipoxia | |
| JPWO2021085653A5 (enExample) | ||
| RU2018113339A (ru) | Фармацевтическое соединение | |
| JP2014530243A (ja) | Ａｒｒｙ−３８０の多形体、選択的ｈｅｒｂ２阻害剤、およびそれらを含有する薬学的組成物 | |
| WO2013104263A1 (zh) | 多羟基苯并吡喃酮类化合物的合成及其抗肿瘤作用 | |
| WO2007143483A2 (en) | Combination of pazopanib and lapatinib for treating cancer | |
| JP2022512826A (ja) | ＭｅｔＡＰ２阻害剤のバイオマーカーとその応用 | |
| JPWO2019209896A5 (enExample) | ||
| JP7296070B2 (ja) | がん免疫療法アジュバント | |
| CN110461836B (zh) | 一种选择性抑制激酶化合物及其用途 | |
| JP2019522681A5 (enExample) | ||
| CN114599360A (zh) | 4-氨基-咪唑并喹啉化合物及其用途 | |
| CN117062819A (zh) | 多环化合物及其用途 | |
| JPWO2020037091A5 (enExample) | ||
| CA2460347A1 (en) | 3-glyoxlylamideindoles for treating cancer | |
| US20090005406A1 (en) | Cancer Treatment Method | |
| JPWO2020037092A5 (enExample) | ||
| JPWO2021076691A5 (enExample) | ||
| RU2018119935A (ru) | 1,4-дикарбонилпиперидильные производные | |
| JP2018528949A5 (enExample) |